All Stories

  1. A cost-effectiveness analysis of a hydration response technology dressing in the treatment of venous leg ulcers in the UK

    Article • Journal of Wound Care, March 2018, Mark Allen Group

    Stefan Walzer, Dr Karen Ousey

  2. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum]

    Article • ClinicoEconomics and Outcomes Research, January 2017, Dove Medical Press

    Monica Canciani, Stefan Walzer

  3. Administrative risk quantification of subcutaneous and intravenous therapies in Italian centers utilizing the Failure Mode and Effects Analysis approach

    Article • ClinicoEconomics and Outcomes Research, August 2016, Dove Medical Press

    Monica Canciani, Stefan Walzer

  4. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey

    Article • ClinicoEconomics and Outcomes Research, May 2016, Dove Medical Press

    Monica Canciani, Stefan Walzer

  5. Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy

    Article • Expert Review of Anticancer Therapy, September 2014, Taylor & Francis

    Stefan Walzer

  6. Health economics evidence for medical nutrition: are these interventions value for money in integrated care?

    Article • ClinicoEconomics and Outcomes Research, May 2014, Dove Medical Press

    Daniel Droeschel, Stefan Walzer

  7. Health economic analyses in medical nutrition: a systematic literature review

    Article • ClinicoEconomics and Outcomes Research, March 2014, Taylor & Francis

    Daniel Droeschel, Stefan Walzer

  8. Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey

    Article • ClinicoEconomics and Outcomes Research, May 2013, Taylor & Francis

    Stefan Walzer

  9. Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain

    Article • ClinicoEconomics and Outcomes Research, October 2012, Taylor & Francis

    Stefan Walzer

  10. Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy

    Article • ClinicoEconomics and Outcomes Research, September 2012, Taylor & Francis

    Stefan Walzer

  11. Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe

    Article • ClinicoEconomics and Outcomes Research, September 2012, Taylor & Francis

    Stefan Walzer